Vericel (US:VCEL)2021-12-03 16:36Financial Highlights - Vericel reported total net revenue of $124.2 million in 2020[4] - The company experienced approximately 25% revenue CAGR since the launch of MACI in 2017[4] - As of September 30, 2021, Vericel had approximately $119 million in cash and investments with no debt[8, 65] - Through Q3 2021, total revenue growth was 38%, with Epicel year-to-date revenue exceeding full-year 2020 revenue[6] Product Portfolio & Market - Vericel focuses on sports medicine and severe burn care markets with innovative cell therapies and specialty biologics[3] - The company's portfolio includes MACI for cartilage repair, Epicel for permanent skin replacement, and NexoBrid for eschar removal[3] - The addressable market for cartilage repair in the U S is over $2 billion[4, 36] - The addressable market for the burn franchise in the U S is over $200 million[60] MACI (Sports Medicine) - MACI demonstrated statistically significantly greater improvement in KOOS pain and function scores compared to microfracture at year 2[23] - Published MACI rehabilitation protocols achieve full weight-bearing in 6-8 weeks compared to 10-12 weeks for published Carticel rehabilitation protocols[35] NexoBrid & Epicel (Severe Burns) - NexoBrid is an investigational product in the U S with orphan biologic designation[49, 50] - Epicel is the only FDA-approved permanent skin replacement for adult and pediatric patients with full-thickness burns[51] - Data demonstrates lower mortality rate in Epicel patients compared to National Burn Repository[55]